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CASE PRESENTATION
Patient 1: A 78-year-old woman presented with a 3-day
history of abdominal pain, nausea, vomiting, and
anorexia. Past medical history included type 2 diabetes
mellitus, autoimmune hepatitis, hypertension, and
ulcerative colitis with colectomy. Medications included
metformin 1500 mg twice daily (6 months), glyburide,
rofecoxib, furosemide, levothyroxine, prednisone,
azathioprine, and propanolol. On admission, she was
hypothermic (34.41C), had blood pressure, 115/51 mm Hg,
pulse 104 beats/min, and trace of lower extremity edema.
The rest of the physical examination was unremarkable.
Arterial blood gases showed pH 7.0, pCO2 7 mm Hg, tCO2
2 mEq/l. She was transferred to the intensive care unit and
intubated for respiratory failure. Serum creatinine was
8.9 mg/dl (baseline, 1.0 mg/dl; estimated glomerular
filtration rate (eGFR) 57 ml/min/1.732 by the Modification
of Diet in Renal Disease Study (MDRDS) formula); serum
lactate 9.6 mg/dl; serum metformin 17mg/ml (therapeutic
level 1–2mg/ml). Liver enzymes were normal. Urinalysis:
protein 2þ and moderate blood. Renal ultrasound ruled
out obstruction. Echocardiogram showed normal left
ventricular function and all fluid cultures were negative.
Pertinent laboratory findings are shown in Table 1.
Patient 2: A 64-year-old woman presented with nausea
and vomiting. Past medical history included type 2
diabetes mellitus, hyperlipidemia, and hypertension.
Medications included metformin 500 mg twice daily
(3 months), lisinopril, and ibuprofen for arthritis. On
admission, she was hypothermic (34.51C), hypotensive
(blood pressure, 85/38 mm Hg), and tachypneic
(28 breaths/min). The rest of the physical examination was
unremarkable. Arterial blood gases showed pH 6.78, pCO2
15 mm Hg, and tCO2 3 mEq/l. She was transferred to the
intensive care unit and intubated for respiratory failure.
Serum creatinine was 5.9 mg/dl (1.0 mg/dl 8 months
earlier and eGFR 59 ml/min/1.732 by the MDRDS formula);
serum lactate 22 mg/dl; serum metformin 31mg/ml. Liver
enzymes were mildly elevated. Urinalysis: blood 3þ and
protein negative. All cultures and toxicology tests
were negative. Non-contrast computer tomography
showed no intra-abdominal or pelvic abscesses. Cardiac
enzymes and electrocardiogram were not suggestive of
myocardial injury. Pertinent laboratory findings are shown
in Table 1.
CLINICAL FOLLOW-UP
Both patients were elderly women with type 2 diabetes
mellitus taking metformin, presenting with volume deple-
tion, acute kidney injury, and an elevated anion gap
metabolic acidosis. Lactic acidosis was considered the most
probable cause of the acidosis, although the initial source was
not apparent. Metformin-associated lactic acidosis (MALA)
was suspected and serum metformin level was measured and
found elevated. Intravenous bicarbonate was used initially in
the intensive care unit in an attempt to stabilize the patients
before dialysis access placement. In patient 1, intermittent
hemodialysis was initiated with an F70NR dialysis membrane
(Fresenius, polysulfone), blood flow rate 250 ml/min, and
dialysate containing bicarbonate 28 mEq/l. Serum lactate and
metformin levels decreased (1.5 mg/dl and 4.4 mg/ml, respec-
tively) after a 4-h dialysis session and the acidosis was
corrected (Figure 1). Another 4-h dialysis session was
performed the following day because of persistent renal
dysfunction. Eventually, her kidney function recovered
(serum creatinine 1.1 mg/dl and eGFR 51 ml/min/1.732)
and she was discharged without need for further dialysis.
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In patient 2, sustained low-efficiency dialysis (SLED) was
initiated with an F5 dialysis membrane (Fresenius, poly-
sulfone), blood flow rate 200 ml/min, and dialysate contain-
ing bicarbonate 28 mEq/l. SLED was discontinued 15 h later.
Serum lactate and metformin levels decreased and the
acidosis was corrected (Figure 2). The patient received four
additional intermittent hemodialysis sessions because of slow
renal function recovery. Ten days later, her kidney function
improved and she was discharged without need for further
dialysis.
DIAGNOSIS
Both patients were diagnosed with acute kidney injury and
metabolic acidosis with an elevated anion gap, thought to be
due to MALA.
DISCUSSION
In 1995, the Food and Drug Administration approved the use
of metformin, the only biguanide currently available in the
United States. Phenformin, its congener, was withdrawn in
1977 because of an association with fatal lactic acidosis.
Characteristics
Metformin hydrochloride is a dimethylbiguanide with
molecular formula C4H11N5 HCL.1 It is an antihyperglyce-
mic agent that improves insulin sensitivity without decreas-
ing the glucose concentration below normal range.
Metformin is 90–100% renally excreted as unchanged drug,
and clearance is reduced with renal dysfunction.2,3 The
plasma half-life is 1.5–4.9 h in healthy volunteers. Metformin
has high water solubility, molecular weight 165.63, negligible
protein binding in serum, and a large volume of distribution
(63–276 l), because it diffuses freely into the intracellular
compartment and binds to microsomes.4
Benefits versus risks
The beneficial effects of metformin therapy for overweight
and type 2 diabetic patients were demonstrated by the United
Kingdom Prospective Diabetes Study (UKPDS),5 and it has
become the oral agent of choice for such patients. Nausea,
vomiting, diarrhea, and anorexia are common side effects,
but MALA, a potentially life-threatening metabolic disorder,
can also occur. Diabetic patients, not taking metformin, are
already at increased risk for developing lactic acidosis
associated with hypoxemia because of atherosclerosis and
microvascular disease, and/or in sepsis or volume depletion.6
Metformin may increase this risk.
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Figure 1 | Effect of intermittent hemodialysis for 4 h on serum
lactate, metformin, and bicarbonate levels. Note the rapid
decrease of both metformin and serum lactate level and the
reciprocal increase of the bicarbonate level.
Table 1 | Laboratory data of the patients on admission
Initial presentation Patient 1 Patient 2
Reference
values
Arterial blood gas
pH 7 6.78 7.35–7.45
pCO2 (mm Hg) 7 15 35–45
tCO2 (mEq/l) 2 3 —
Serum Electrolytes
Na+ (mEql/l) 133 146 136–145
K+ (mEq/l) 6.7 6.6 3.5–5.5
Cl (mEq/l) 102 100 96–110
HCO3 (mEq/l) 5 5 24–32
Anion Gap 26 41 8–12
Corrected Ca2+ (mEq/l) 9.1 9.0 8.5–10.5
Phosphate [PO4 ] (mg/dl) 8.1 13.6 2.5–4.5
Serum blood urea nitrogen (mg/dl) 120 32 10–26
Serum glucose (mg/dl) 184 143 70–100
Serum creatinine (mg/dl) 8.9 5.9 0.7–1.5
Serum lactate (mg/dl) 9.6 22 0.7–2.1
Serum metformin level (mg/ml) 17 31 1–2
Aspartate aminotransferase (AST) (U/l) 36 242 8–50
Alanine aminotransferase (ALT) (U/l) 27 87 15–75
Complete blood count
White Blood Cells K/cmm 11.7 40 4–10.4
Hemoglobin (gm/dl) 10.5 12.1 13.8–17.3
Platelets K/cmm 220 486 141–320
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Figure 2 | Effect of sustained low-efficiency dialysis (SLED) over
15 h in the serum lactate, metformin, and bicarbonate levels.
Note the rapid decrease of both metformin and serum lactate levels
and the reciprocal increase of the bicarbonate level.
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Pathogenesis of MALA
Several mechanisms have been postulated to explain this
condition. Metformin may cause a shift in the intracellular
redox potential away from aerobic to anaerobic metabolism.
In experimental models of biguanide-associated lactic acido-
sis, this process has been observed in gastrointestinal tract
cells, the site of metformin accumulation, and these cells
appear as the main lactic acid production site in this
condition.7 The liver takes up approximately 60% and
oxidizes the lactate to pyruvate, which is converted by
pyruvate carboxylase to glucose via gluconeogenesis. Bigua-
nides are known to decrease intracellular pH. This effect
reduces lactic acid utilization by decreasing liver uptake of
lactate, and suppression of gluconeogenesis by reduction in
the hepatic activity of pyruvate carboxylase. Increased
hepatocyte anaerobic metabolism also increases lactic acid
production resulting in further decreases in lactate uptake.
Furthermore, biguanides can have a negative inotropic effect
on cardiac muscle, resulting in decreased cardiac output,
decreasing further hepatic lactate clearance.8 Increased
production and decreased utilization of lactic acid predisposes
patients taking biguanides to increased serum concentrations
and may result in lactic acidosis. Metformin is less likely than
phenformin to cause lactic acidosis because metformin
concentrates in the cytosol, has less effect on mitochondrial
glucose oxidation, less protein binding, shorter half-life than
phenformin, and it is not metabolized by the liver.6
Clinical features
MALA can present with anorexia, nausea, vomiting, and
abdominal pain. Other serious effects include hypotension,
respiratory failure, arrhythmias, and hypothermia.9,10 La-
boratory tests suggesting lactic acidosis include serum lactate
levels 44 mg/dl, serum pH o7.35, and an elevated anion
gap. Our patients presented with gastrointestinal symptoms,
hypothermia, and respiratory failure requiring intubation.
Serum lactate and metformin levels were elevated. Although a
correlation between serum lactate and metformin levels has
been observed in both animal and human studies,11 in the
latter, it was only noted in patients with high metformin
levels and the relationship was confounded by other lactic
acid-promoting conditions.
Epidemiology
MALA is believed to be rare. A recent Cochrane review
reported an incidence approximating 1–5 cases/100 000 pa-
tient-years. This study was looking at prospective compara-
tive trials or observational cohort studies and concluded that,
‘there is no evidence to suggest that metformin is associated
with an increased risk of lactic acidosis, or with increased
levels of serum lactate, compared to other glucose-lowering
treatments if prescribed under the study conditions, taking
into account the current suggested contraindications.’12
However, a review of the literature, as well as our own clinical
experience, suggests that MALA may be more prevalent
(30 cases/100 000 patient-years).13 Confidence generated by
the UKPDS results5 has possibly led to more frequent
prescribing, and thus metformin may be used in patients with
conditions that place them at risk for developing renal
dysfunction and lactic acidosis. A recent study showed that
62% of 204 hospitalized patients taking metformin had one or
more contraindications or precautionary conditions.14
Indications and contraindications
Metformin use is currently contraindicated in people with
serum creatinine X1.5 mg/dl (men) and X1.4 mg/dl
(women), heart failure, liver failure, or older than 80 years
of age. According to the manufacturer’s product information,
doses over 2000 mg daily can also cause lactic acidosis.
Herein, both patients had serum creatinine of 1 mg/dl, and
neither had known liver or heart failure. Patient 1 was
younger than the contraindicated age and on a recommended
metformin dose (1000 mg/day), whereas patient 2 was close
to the age breakpoint and on an inappropriately high dose
(3000 mg/day). Nonetheless, both patients suddenly devel-
oped volume depletion and acute kidney injury. In addition,
patient 2 was taking an angiotensin-converting enzyme
inhibitor for hypertension and over the counter ibuprofen,
whereas patient 1 was on a diuretic and rofecoxib, regimens
that predispose to renal dysfunction when effective volume
depletion is present, and allow lactic acid accumulation. This
suggests that the established contraindications for metformin
use may not protect a large number of people who have
common conditions that put them at risk, including elderly
type 2 diabetic patients on angiotensin-converting enzyme
inhibitor, angiotensin II receptor blockers, non-steroidal
anti-inflammatory drugs, cyclooxygenase-2 inhibitors, or
diuretics. It may be advisable to patients temporarily
discontinue these medications, as well as metformin, when
acutely ill or on admission to a hospital.
Another important observation is that the serum creati-
nine of 1.5 mg/ml (men) and 1.4 mg/ml (women) is not a
reliable measure of renal impairment. Chronic kidney disease
(CKD) is best identified by the eGFR, easily calculated by the
MDRDS formula15 or the Cockcroft–Gault equation. Accord-
ing to the National Kidney Foundation Disease Outcomes
Quality Initiative CKD staging, both our patients had CKD
stage 3 (eGFR 30–60 ml/min/1.73m2) before presentation
despite ‘normal’ serum creatinine levels. This suggests that
identification of patients at risk would improve if CKD
staging were incorporated into routine clinical practice.
Treatment
MALA carries a mortality rate of 50% if not treated, and
supportive care is the mainstay of treatment. This includes
eliminating the medication, correcting the acid-base imbal-
ance, and treating any concomitant disease.8 Intravenous
bicarbonate is often administered in an attempt to ameliorate
the effects of the acidosis, particularly when there is
ventilatory fatigue and hemodynamic instability,16 although
this treatment has not been shown to improve either
hemodynamic stability or overall survival.17 The ability of
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bicarbonate to correct the acidosis is limited by complica-
tions from rapid administration of hypertonic fluid and by
alkali-induced stimulation of lactic acid production.6 Inter-
mittent and continuous hemodialysis have been used for
treatment of MALA, allowing correction of acidosis by
isotonic and isovolemic bicarbonate supplementation and
removal of metformin and lactate from the circulation.18,19
Metformin’s low molecular weight and lack of protein
binding makes it possible for effective clearance with
conventional dialysis modalities.20 Extended treatment ses-
sions are needed because of the rebound increase in serum
lactate levels reported with short sessions, possibly due to
increased lactic acid production from the high delivery of
bicarbonate.6 Total drug removal is difficult due to the large
volume of distribution and intracellular binding. Patient 1
received intermittent hemodialysis for 4 h initially and 4 h the
following day. In patient 2, SLED was used for 15 h. The
serum lactate and metformin levels decreased, acidosis was
corrected, and both recovered with normal or near normal
kidney function (Figures 1 and 2).
Conclusions and suggestions
Patients without the established contraindications to met-
formin use remain at risk for developing potentially fatal
lactic acidosis, if they have predisposing conditions for
developing acute renal dysfunction. These include intercur-
rent illness that cause volume depletion in association with
conditions or medications, which alter intrarenal hemody-
namics such as advanced age, hypertension, diabetes, known
CKD, and/or the use of angiotensin-converting enzyme
inhibitor, angiotensin II receptor blockers, non-steroidal
anti-inflammatory drugs, and diuretics. Metformin appears
to decrease the risk of diabetes-related end points in
overweight diabetic patients, and is associated with less
weight gain and fewer hypoglycemic attacks than insulin and
sulfonylureas making it the therapy of choice in these
patients.5 However, it should be used with the knowledge that
these are the same patients who are vulnerable to acute and
chronic changes in renal function, and thus there should be
contingency plans to stop or adjust the dose if such
conditions occur. Renal function should be measured in all
persons with diabetes at least yearly, more often in those with
proteinuria or known CKD, and at any time when renal
function is threatened by an intercurrent illness. Calculating
the eGFR using the serum creatinine level with either the
MDRDS or Cockcroft–Gault equations is the best measure to
use. Empiric decrements in the metformin dose should
accompany reduction in renal function. Monitoring serum
metformin levels has not been shown to be useful and is not
recommended. Patients should be educated to contact a
health care provider and hold metformin (as well as
angiotensin-converting enzyme inhibitor, angiotensin II
receptor blockers, diuretics, and non-steroidal anti-inflam-
matory drugs), if diarrhea or vomiting together with inability
to take anything by mouth exists for several days. Finally,
SLED or intermittent hemodialysis can provide an excellent
and highly efficient treatment modality for MALA resulting
in timely and favorable outcomes.
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